Evidence map›Paper›PMID 35543207›Full record

ArticleAnnals of medicine2022

Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.

Zhangqiang Xiang, Xiangyu Deng, Wenfeng He, Qian Yang, Laichao Ni, Marzieh Dehghan Shasaltaneh, Mazaher Maghsoudloo, Gang Yang, Jingbo Wu, Saber Imani and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. [Research Progress on Local Treatment of Malignant Pleural Effusion].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Zhangqiang XiangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Xiangyu DengDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Wenfeng HeDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Qian YangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Laichao NiDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Marzieh Dehghan ShasaltanehDepartment of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.
Mazaher MaghsoudlooLaboratory of Systems Biology and Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Gang YangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jingbo WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Saber ImaniDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Qinglian WenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Affiliated Hospital of Southwest Medical University · CNAnyang Hospital of Traditional Chinese Medicine · CNUniversity of Tehran · IRUniversity of Zanjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion.

methodsIn this study, we established Lewis lung cancer (LLC) xenograft mouse models to compare the therapeutic effect of APA and BEV in combination with cisplatin (CDDP) against MPE. The anti-tumour and anti-angiogenic effects of this combination therapy were evaluated by

resultsThe triple drug combination significantly prolonged the overall survival of the tumour-bearing mice by reducing MPE and glucose metabolism and was more effective in lowering VEGF/soluble VEGFR-2 levels in the serum and pleural exudates compared to either of the monotherapies. Furthermore, CDDP + APA + BEV promoted

conclusionsMechanistically, LLC-induced MPE was inhibited by targeting the VEGF-MEK/ERK pathways. Further studies are needed to establish the synergistic therapeutic effect of these drugs in NSCLC patients with MPE.KEY MESSAGESCombined treatment of MPE with apatinib, bevacizumab and cisplatin can prolong the survival time of mice, reduce the content of MPE, decrease the SUV

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPleural Effusion, MalignantAnimalsBevacizumabCisplatinHumansMicePositron Emission Tomography Computed TomographyVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2BevacizumabCisplatinVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2apatinibbevacizumabcisplatinMalignant pleural effusionnon-small-cell lung cancervascular endothelial growth factor

Identifiers

PMID35543207
PMCPMC9103356
OpenAlexW4280499295

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.